Clinical-stage biopharmaceutical company focused on cancer immunotherapy.
iTeos Therapeutics, Inc. is a dynamic clinical-stage biopharmaceutical company dedicated to advancing immuno-oncology therapeutics for the benefit of patients worldwide. Founded in 2011 and based in Watertown, Massachusetts, the company is at the forefront of discovering and developing innovative treatments that harness the power of the immune system to combat cancer.
At the heart of iTeos Therapeutics' robust pipeline is inupadenant, a Phase 2 clinical trial candidate known for its role as a small molecule antagonist targeting the adenosine A2AR receptor. Additionally, the company is progressing EOS-448, a promising Phase 1/2 clinical trial therapy designed as an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains). EOS-448 not only engages the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages but also enhances antibody-dependent cellular cytotoxicity (ADCC) activity.
Committed to innovation and therapeutic advancement, iTeos Therapeutics leverages cutting-edge research to expand its portfolio and address critical unmet needs in oncology. By focusing on novel mechanisms and strategic partnerships, the company aims to redefine treatment paradigms and improve outcomes for cancer patients globally.
Through collaborative efforts and a steadfast dedication to scientific excellence, iTeos Therapeutics continues to drive forward in its mission to develop transformative therapies that enhance the body's natural immune response against cancer cells. With a strong foundation in immuno-oncology, the company remains poised for growth and impact in the evolving landscape of cancer treatment.